Nature Reviews Bioengineering, Journal Year: 2024, Volume and Issue: 2(11), P. 916 - 929
Published: Sept. 23, 2024
Language: Английский
Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)
Published: April 27, 2023
Protein-based therapeutics have led to new paradigms in disease treatment. Projected be half of the top ten selling drugs 2023, proteins emerged as rivaling and, some cases, superior alternatives historically used small molecule-based medicines. This review chronicles both well-established and emerging design strategies that enabled this paradigm shift by transforming protein-based structures are often prone denaturation, degradation, aggregation vitro vivo into highly effective therapeutics. In particular, we discuss for creating with increased affinity targetability, enhanced stability pharmacokinetics, improved cell permeability, reduced amounts undesired immunogenicity.
Language: Английский
Citations
173
Nature Reviews Bioengineering, Journal Year: 2023, Volume and Issue: 1(6), P. 426 - 439
Published: March 21, 2023
Language: Английский
Citations
82
Nature Reviews Bioengineering, Journal Year: 2023, Volume and Issue: 1(5), P. 314 - 328
Published: Feb. 22, 2023
Language: Английский
Citations
62
Advanced Materials, Journal Year: 2023, Volume and Issue: unknown
Published: July 12, 2023
Abstract Natural living materials serving as biotherapeutics exhibit great potential for treating various diseases owing to their immunoactivity, tissue targeting, and other biological activities. In this review, the recent developments in engineered materials, including mammalian cells, bacteria, viruses, fungi, microalgae, plants, active derivatives that are used summarized. Further, future perspectives challenges of such material‐based discussed provide considerations advances biomedical applications.
Language: Английский
Citations
56
Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 191 - 191
Published: Feb. 15, 2025
Using plants as bioreactors, molecular farming has emerged a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, reduced risk contamination with human pathogens. Recent advancements in gene editing, transient expression systems, nanoparticle-based delivery technologies have significantly enhanced efficiency versatility plant-based systems. Particularly vaccine development, demonstrated its potential notable successes such Medicago's Covifenz COVID-19, illustrating capacity platforms to address global health emergencies rapidly. Furthermore, edible vaccines opened new avenues mainly settings low resources where cold chain used conventional logistics is challenge. However, optimization protein yield stability, complexity purification processes, regulatory hurdles are some challenges that still remain. review discusses current status development using operational mechanisms plant platforms, major applications prevention infectious diseases, developments, nanoparticle-mediated cancer vaccines. The discussion will also touch on ethical considerations, framework, future trends respect transformative plant-derived ensuring greater accessibility cost-effectiveness vaccination. field holds great promise disease area and, indeed, personalized medicine biopharmaceuticals near future.
Language: Английский
Citations
3
Frontiers in Bioengineering and Biotechnology, Journal Year: 2022, Volume and Issue: 10
Published: March 8, 2022
Spider silk threads have exceptional mechanical properties such as toughness, elasticity and low density, which reach maximum values compared to other fibre materials. They are superior even Kevlar steel. These extraordinary stem from long length specific protein structures. proteins can consist of more than 20,000 amino acids. Polypeptide stretches account for 90% the whole protein, these domains be repeated a hundred times. Each repeat unit has function resulting in final silk. make them attractive innovative material development medical or technical products well cosmetics. However, with livestock breeding spiders it is not possible high volumes due cannibalistic behaviour animals. In order obtain spider (spidroins) on large scale, recombinant production attempted various expression systems plants, bacteria, yeasts, insects, silkworms, mammalian cells For viable large-scale production, cost-effective efficient needed. This review describes different types silk, their structures discusses difficult-to-express host organisms an emphasis plant systems.
Language: Английский
Citations
61
Biotechnology Advances, Journal Year: 2022, Volume and Issue: 62, P. 108074 - 108074
Published: Dec. 5, 2022
Language: Английский
Citations
58
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: July 9, 2024
Abstract Excessive exercise is an etiological factor of intervertebral disc degeneration (IVDD). Engineered extracellular vesicles (EVs) exhibit excellent therapeutic potential for disease-modifying treatments. Herein, we fabricate self-powered triboelectric-responsive microneedle (MN) assay with the sustainable release optogenetically engineered EVs IVDD repair. Mechanically, promotes cytosolic DNA sensing-mediated inflammatory activation in senescent nucleus pulposus (NP) cells (the master cell population IVD homeostasis maintenance), which accelerates IVDD. TREX1 serves as a crucial nuclease, and disassembly TRAM1-TREX1 complex disrupts subcellular localization TREX1, triggering TREX1-dependent genomic damage during NP senescence. Optogenetically deliver TRAM1 protein into cells, effectively reconstructs elimination function TREX1. Triboelectric nanogenerator (TENG) harvests mechanical energy triggers controllable EVs. Notably, EV-based targeting treatment strategy used IVDD, showing promising clinical degeneration-associated disorders.
Language: Английский
Citations
14
Plant Biotechnology Journal, Journal Year: 2024, Volume and Issue: 22(8), P. 2282 - 2300
Published: April 29, 2024
Summary Antimicrobial peptides (AMPs) are emerging as next‐generation therapeutics due to their broad‐spectrum activity against drug‐resistant bacterial strains and ability eradicate biofilms, modulate immune responses, exert anti‐inflammatory effects improve disease management. They produced through solid‐phase peptide synthesis or in yeast cells. Molecular farming, i.e. the production of biologics plants, offers a low‐cost, non‐toxic, scalable simple alternative platform produce AMPs at sustainable cost. In this review, we discuss advantages molecular farming for producing clinical‐grade AMPs, advances expression purification systems cost advantage industrial‐scale production. We further review how ‘green’ is filling sustainability gap, streamlining patent regulatory approvals enabling successful clinical translations that demonstrate future potential by farming. Finally, challenges need be addressed fully realize farming‐based AMP therapeutics.
Language: Английский
Citations
11
Biomacromolecules, Journal Year: 2022, Volume and Issue: 23(4), P. 1812 - 1825
Published: March 28, 2022
Cowpea mosaic virus (CPMV) is a potent immunogenic adjuvant and epitope display platform for the development of vaccines against cancers infectious diseases, including coronavirus disease 2019. However, proteinaceous CPMV nanoparticles are rapidly degraded in vivo. Multiple doses therefore required to ensure long-lasting immunity, which not ideal global mass vaccination campaigns. Therefore, we formulated injectable hydrogels achieve slow particle release prolonged immunostimulation. Liquid formulations were prepared from chitosan glycerophosphate (GP) before homogenization with particles at room temperature. The containing high-molecular-weight 0-4.5 mg mL-1 gelled 37 °C (5-8 min) slowly released cyanine 5-CPMV vitro Importantly, when hydrogel displaying severe acute respiratory syndrome 2 spike protein 826 (amino acid 809-826) was administered mice as single subcutaneous injection, it elicited an antibody response that sustained over 20 weeks, associated shift Th1 Th2 bias. Antibody titers improved later time points (weeks 16 20) comparing versus soluble vaccine candidates; furthermore, candidates retained We conclude can be effectively chitosan/GP intact several months conserved immunotherapeutic efficacy. epitope-labeled offers promising single-dose prevention future pandemics well strategy develop plant virus-based nanomedicines.
Language: Английский
Citations
39